company background image
MSLP

MusclePharm OTCPK:MSLP Stock Report

Last Price

US$0.18

Market Cap

US$6.0m

7D

-5.8%

1Y

-91.7%

Updated

01 Jul, 2022

Data

Company Financials
MSLP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

MSLP Stock Overview

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally.

MusclePharm Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MusclePharm
Historical stock prices
Current Share PriceUS$0.18
52 Week HighUS$2.17
52 Week LowUS$0.12
Beta0.20
1 Month Change0%
3 Month Change-37.93%
1 Year Change-91.71%
3 Year Change-48.28%
5 Year Change-90.00%
Change since IPO-99.98%

Recent News & Updates

Shareholder Returns

MSLPUS Personal ProductsUS Market
7D-5.8%-4.5%-2.5%
1Y-91.7%-24.0%-21.2%

Return vs Industry: MSLP underperformed the US Personal Products industry which returned -24.7% over the past year.

Return vs Market: MSLP underperformed the US Market which returned -21.7% over the past year.

Price Volatility

Is MSLP's price volatile compared to industry and market?
MSLP volatility
MSLP Average Weekly Movement31.9%
Personal Products Industry Average Movement11.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: MSLP is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 32% a week.

Volatility Over Time: MSLP's weekly volatility has increased from 23% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200621Ryan Drexlerhttps://www.musclepharm.com

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products.

MusclePharm Fundamentals Summary

How do MusclePharm's earnings and revenue compare to its market cap?
MSLP fundamental statistics
Market CapUS$6.03m
Earnings (TTM)-US$19.26m
Revenue (TTM)US$50.02m

0.1x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MSLP income statement (TTM)
RevenueUS$50.02m
Cost of RevenueUS$46.83m
Gross ProfitUS$3.19m
Other ExpensesUS$22.45m
Earnings-US$19.26m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin6.38%
Net Profit Margin-38.51%
Debt/Equity Ratio-58.9%

How did MSLP perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MSLP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MSLP?

Other financial metrics that can be useful for relative valuation.

MSLP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA-2.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MSLP's PS Ratio compare to its peers?

MSLP PS Ratio vs Peers
The above table shows the PS ratio for MSLP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.2x
CVSI CV Sciences
0.3x13.3%US$5.2m
GLUC Glucose Health
8xn/aUS$7.5m
SLGD Scott's Liquid Gold-Inc
0.3xn/aUS$8.8m
EWLU Merion
4xn/aUS$4.8m
MSLP MusclePharm
0.1xn/aUS$6.0m

Price-To-Sales vs Peers: MSLP is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (3.2x).


Price to Earnings Ratio vs Industry

How does MSLP's PE Ratio compare vs other companies in the US Personal Products Industry?

Price-To-Sales vs Industry: MSLP is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Personal Products industry average (1.3x)


Price to Sales Ratio vs Fair Ratio

What is MSLP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MSLP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MSLP's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MSLP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MSLP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MSLP's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MSLP's PEG Ratio to determine if it is good value.


Discover undervalued companies

  • Take a look at our analysis of MSLP's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through MusclePharm regulatory filings here.

Future Growth

How is MusclePharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.7%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MusclePharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of MSLP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MusclePharm's filings and announcements here.

Past Performance

How has MusclePharm performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-6.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MSLP is currently unprofitable.

Growing Profit Margin: MSLP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MSLP is unprofitable, and losses have increased over the past 5 years at a rate of 6.2% per year.

Accelerating Growth: Unable to compare MSLP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MSLP is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (37.3%).


Return on Equity

High ROE: MSLP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is MusclePharm's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MSLP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MSLP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MSLP has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MSLP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MSLP has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: MSLP is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Dividend

What is MusclePharm current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MSLP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MSLP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MSLP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MSLP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MSLP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Ryan Drexler (51 yo)

6.25yrs

Tenure

US$1,639,817

Compensation

Mr. Ryan Charles Drexler serves as the Chief Executive Officer of Consac, LLC. Mr. Drexler serves as Chief Executive Officer at MusclePharm Corporation and served as its President. He has been Executive Ch...


CEO Compensation Analysis

Compensation vs Market: Ryan's total compensation ($USD1.64M) is above average for companies of similar size in the US market ($USD765.69K).

Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MSLP's management team is seasoned and experienced (6.3 years average tenure).


Board Members

Experienced Board: MSLP's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MusclePharm Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: MusclePharm Corporation
  • Ticker: MSLP
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: US$6.026m
  • Shares outstanding: 33.48m
  • Website: https://www.musclepharm.com

Number of Employees


Location

  • MusclePharm Corporation
  • 6728 West Sunset Road
  • Suite 130
  • Las Vegas
  • Nevada
  • 89119
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/01 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.